Coronary Artery DiseasePHOTONNCT07699679
Photobiomodulation in Coronary Artery Bypass Grafting With No-Touch vs Conventional Saphenous Vein Harvesting.
A study testing Photobiomodulation Therapy, Conventional Saphenous Vein Harvesting and No-Touch Saphenous Vein Harvesting in people with Coronary Artery Disease and Coronary Artery Bypass Graft (CABG), run by Federal University of São Paulo at 1 site in Brazil.
Trial summary
This randomized, double-blind clinical trial aims to evaluate the impact of photobiomodulation therapy on postoperative outcomes in patients undergoing coronary artery bypass grafting (CABG). Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Coronary Artery Disease, Coronary Artery Bypass Graft (CABG), Surgical Wound Healing
- What is being tested?
- Photobiomodulation Therapy, Conventional Saphenous Vein Harvesting and No-Touch Saphenous Vein Harvesting
- Type of treatment
- Medical device, Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 292 participants
- Where
- 1 siteBrazil
- Study dates
- Jan 2027to Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients diagnosed with coronary artery disease scheduled to undergo elective coronary artery bypass grafting (CABG)
- Use of the saphenous vein as a graft for myocardial revascularization
- Ability to understand the study procedures and provide written informed consent
Who cannot join
- Emergency coronary artery bypass surgery
- Previous surgery in the lower limb that prevents saphenous vein harvesting
- Active infection at the surgical site or lower limb
- Severe peripheral arterial disease in the lower limbs
- Hemodynamic instability preventing study protocol procedures
- Participation in another interventional clinical trial that may interfere with the outcomes of this study
- Patients unable to perform postoperative functional capacity assessments
- Individuals with highly pigmented skin or sensibility that may alter light absorption and penetration of the photobiomodulation therapy.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Brazil1 site
Hospital São Paulo, Federal University of São Paulo
São Paulo, São Paulo, 04021001
About this study
Official title: Impact of Photobiomodulation in Coronary Artery Bypass Surgery: Comparison Between No-Touch and Conventional Saphenous Vein Harvesting Techniques on Clinical Outcomes, Functional Capacity, and Wound Healing: A Randomized Clinical Trial
This randomized, double-blind clinical trial aims to evaluate the impact of photobiomodulation therapy on postoperative outcomes in patients undergoing coronary artery bypass grafting (CABG). The study will compare two techniques for saphenous vein graft harvesting: the conventional technique and the no-touch technique. Participants will be randomly allocated into four groups: conventional harvesting with sham laser, conventional harvesting with photobiomodulation, no-touch harvesting with sham laser, and no-touch harvesting with photobiomodulation. The primary objective is to evaluate the effects of photobiomodulation on wound healing and postoperative complications related to the saphenous vein harvesting site. Secondary outcomes include clinical outcomes and functional capacity after surgery. The results may contribute to improving postoperative recovery and optimizing surgical strategies in patients undergoing myocardial revascularization.
Read the detailed description
Cardiovascular diseases remain one of the leading causes of morbidity and mortality worldwide. Coronary artery bypass grafting (CABG) is a widely performed surgical procedure for the treatment of advanced coronary artery disease. The saphenous vein is frequently used as a graft in CABG; however, complications related to vein harvesting, including wound infection, delayed healing, and postoperative pain, remain relevant clinical concerns.
The no-touch technique for saphenous vein harvesting has been proposed as a strategy to preserve the structural integrity of the vein and potentially improve graft patency and reduce local tissue trauma. In addition, photobiomodulation therapy (low-level laser therapy) has demonstrated beneficial effects on tissue repair, inflammation modulation, and wound healing.
This study, named PHOTON Study, is a randomized, double-blind, controlled clinical trial designed to investigate the effects of photobiomodulation therapy in patients undergoing CABG. Participants will be randomized into four groups according to the harvesting technique and the use of photobiomodulation therapy. This study protocol was developed in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines.
Photobiomodulation will be applied using a cluster laser device (E-light, DMC Equipamentos Ltda., Brazil) with a wavelength of 660 nm and output power of 100 mW. The laser will be applied locally along the surgical incision of the saphenous vein harvesting site using a point technique with standardized spacing between application points. The intervention will be performed intraoperatively and during the early postoperative period.
The primary outcomes include wound healing and postoperative complications related to the saphenous vein harvesting site. Secondary outcomes include clinical outcomes and functional capacity following surgery.
This trial may contribute to improving postoperative care and recovery in patients undergoing coronary artery bypass grafting.
- Being tested
- Photobiomodulation Therapy, Sham Laser irradiation, Conventional Saphenous Vein Harvesting, No-Touch Saphenous Vein Harvesting
- Keywords
- Photobiomodulation, Low-Level Laser Therapy, Coronary Artery Bypass Grafting, Saphenous Vein Harvesting, No-Touch Technique, Wound Healing
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Photobiomodulation TherapyDevice
Photobiomodulation will be applied using a cluster laser device (E-light, DMC Equipamentos Ltda., Brazil) with wavelength of 660 nm and output power of 100 mW. The therapy will be applied along the surgical incision of the saphenous vein harvesting site using a point technique with standardized spacing between application points. The intervention will be performed intraoperatively and during the early postoperative period.
Sham Laser irradiationDevice
Simulated photobiomodulation therapy applied using the same laser device without emission of therapeutic laser energy. This sham procedure is used to maintain blinding of participants and outcome assessors.
Conventional Saphenous Vein HarvestingProcedure or surgery
Conventional Saphenous Vein Harvesting refers to the traditional open surgical technique used to obtain the great saphenous vein for grafting procedures, most commonly in coronary artery bypass grafting (CABG). The procedure involves a continuous longitudinal incision along the course of the vein in the lower limb, allowing direct visualization and careful dissection of the vessel from surrounding tissues. Side branches are ligated or clipped, and the harvested vein is subsequently prepared for use as a vascular graft. The technique is performed under sterile surgical conditions by qualified surgeons.
No-Touch Saphenous Vein HarvestingProcedure or surgery
No-Touch Saphenous Vein Harvesting refers to a surgical technique for harvesting the great saphenous vein in which the vein is removed together with a pedicle of surrounding perivascular tissue, avoiding direct manual manipulation and excessive distension of the vessel. The procedure is performed through an open incision under sterile conditions, preserving the vein's adventitia, vasa vasorum, and surrounding connective tissue in order to minimize endothelial injury and maintain vascular integrity. Side branches are carefully ligated or clipped, and the harvested graft is prepared according to institutional surgical protocols for subsequent use in vascular or coronary artery bypass procedures.
| Study group | Role | What they receive |
|---|---|---|
| Conventional Harvesting + Sham laser | Sham comparator | Patients undergoing conventional saphenous vein harvesting with simulated laser application (sham). Receives: Device: Sham Laser irradiation; Procedure: Conventional Saphenous Vein Harvesting |
| Conventional Harvesting + Photobiomodulation | Experimental | Patients undergoing conventional saphenous vein harvesting with active photobiomodulation therapy applied to the surgical incision. Receives: Device: Photobiomodulation Therapy; Procedure: Conventional Saphenous Vein Harvesting |
| No-touch Harvesting + Sham laser | Sham comparator | Patients undergoing saphenous vein harvesting using the no-touch technique with simulated laser application. Receives: Device: Sham Laser irradiation; Procedure: No-Touch Saphenous Vein Harvesting |
| No-touch Harvesting + Photobiomodulation | Experimental | Patients undergoing saphenous vein harvesting using the no-touch technique with active photobiomodulation therapy applied to the surgical incision. Receives: Device: Photobiomodulation Therapy; Procedure: No-Touch Saphenous Vein Harvesting |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of surgical wound complications at the saphenous vein harvesting site
Occurance of one or more surgical wound complications at the saphenous vein harvesting site, including wound infection, necrosis, wound dehiscence, wound drainage or fluid accumulation.
Measured: From postoperative hospitalization to 30 days and 3 months after surgery.
Secondary outcomes (14)
Frequency and severity of adverse responses to photobiomodulation therapy
Assessment of the frequency and severity of adverse reactions associated with photobiomodulation therapy during the hospital stay.
Measured: From the first photobiomodulation therapy session until hospital discharge (Postoperative day 5 or earlier, if discharged).
All-cause mortality
Incidence of death from any cause following coronary artery bypass grafting.
Measured: Hospital discharge, 30 days after discharge and 3 months after discharge
Hospital readmission
Incidence of hospital readmission following coronary artery bypass grafting.
Measured: 30 days and 3 months after discharge
Myocardial infarction
Incidence of myocardial infarction following coronary artery bypass grafting.
Measured: Perioperative, 30 days after discharge and 3 months after discharge.
Length of stay in the intensive care unit (ICU)
Duration of stay in the intensive care unit measured in days after surgery.
Measured: From date of surgery until ICU discharge (assessed up to 30 days).
Length of hospital stay
Total duration of hospital stay measured in days.
Measured: From hospital admission until hospital discharge (assessed up to 60 days)
Plasma interleukin-1 (IL-1) levels
Assessment of plasma IL-1 concentrations measured by enzyme-linked immunosorbent assay (ELISA).
Measured: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Plasma interleukin-6 (IL-6) levels
Assessment of plasma IL-6 concentrations measured by enzyme-linked immunosorbent assay (ELISA).
Measured: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Plasma interleukin-8 (IL-8) levels
Assessment of plasma IL-8 concentrations measured by enzyme-linked immunosorbent assay (ELISA).
Measured: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Plasma interleukin-10 (IL-10) levels
Assessment of plasma IL-10 concentrations measured by enzyme-linked immunosorbent assay (ELISA).
Measured: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Plasma tumor necrosis factor-alpha (TNF-α) levels
Assessment of plasma TNF-α concentrations measured by enzyme-linked immunosorbent assay (ELISA).
Measured: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Thiobarbituric acid reactive substances (TBARS) levels
Assessment of lipid peroxidation by measuring TBARS levels in EDTA plasma samples.
Measured: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Protein carbonylation (CPr) levels
Assessment of oxidative stress through protein carbonylation analysis.
Measured: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Functional capacity assessed by the Six-Minute Walk Test
Functional capacity will be evaluated using Six-Minute Walk Test to assess exercise tolerance and postoperative recovery in patients undergoing coronary artery bypass grafting.
Measured: One day before surgery, five days after surgery, 30 days after hospital discharge and 3 months after discharge.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jul 2026
- Study startJan 2027 (estimated)
- Primary completionAug 2027 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomly assigned to four parallel groups according to the saphenous vein harvesting technique and the use of photobiomodulation therapy: conventional harvesting with sham laser, conventional harvesting with photobiomodulation, no-touch harvesting with sham laser, and no-touch harvesting with photobiomodulation.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 292 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Federal University of São Paulo
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Solange Guizilini, Federal University of São Paulo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07699679
- Sponsor's protocol ID
- 90777725.0.0000.5505
- Acronym
- PHOTON
- Status last verified
- Oct 2026
- First submitted
- 20 Mar 2026
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Photobiomodulation in Coronary Artery Bypass Surgery: Comparison Between No-Touch and Conventional Saphenous Vein Harvesting Techniques on Clinical Outcomes, Functional Capacity, and Wound Healing: A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT07699679
- Acronym / sponsor ID
- PHOTON / 90777725.0.0000.5505
- Keywords
- Photobiomodulation, Low-Level Laser Therapy, Coronary Artery Bypass Grafting, Saphenous Vein Harvesting, No-Touch Technique, Wound Healing
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 292 participants (estimated)
- Lead sponsor
- Federal University of São PauloUniversity, hospital or other
- Study start
- Jan 2027 (estimated)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 13 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, double-blind clinical trial aims to evaluate the impact of photobiomodulation therapy on postoperative outcomes in patients undergoing coronary artery bypass grafting (CABG). The study will compare two techniques for saphenous vein graft harvesting: the conventional technique and the no-touch technique. Participants will be randomly allocated into four groups: conventional harvesting with sham laser, conventional harvesting with photobiomodulation, no-touch harvesting with sham laser, and no-touch harvesting with photobiomodulation. The primary objective is to evaluate the effects of photobiomodulation on wound healing and postoperative complications related to the saphenous vein harvesting site. Secondary outcomes include clinical outcomes and functional capacity after surgery. The results may contribute to improving postoperative recovery and optimizing surgical strategies in patients undergoing myocardial revascularization.
Detailed description
Cardiovascular diseases remain one of the leading causes of morbidity and mortality worldwide. Coronary artery bypass grafting (CABG) is a widely performed surgical procedure for the treatment of advanced coronary artery disease. The saphenous vein is frequently used as a graft in CABG; however, complications related to vein harvesting, including wound infection, delayed healing, and postoperative pain, remain relevant clinical concerns.
The no-touch technique for saphenous vein harvesting has been proposed as a strategy to preserve the structural integrity of the vein and potentially improve graft patency and reduce local tissue trauma. In addition, photobiomodulation therapy (low-level laser therapy) has demonstrated beneficial effects on tissue repair, inflammation modulation, and wound healing.
This study, named PHOTON Study, is a randomized, double-blind, controlled clinical trial designed to investigate the effects of photobiomodulation therapy in patients undergoing CABG. Participants will be randomized into four groups according to the harvesting technique and the use of photobiomodulation therapy. This study protocol was developed in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines.
Photobiomodulation will be applied using a cluster laser device (E-light, DMC Equipamentos Ltda., Brazil) with a wavelength of 660 nm and output power of 100 mW. The laser will be applied locally along the surgical incision of the saphenous vein harvesting site using a point technique with standardized spacing between application points. The intervention will be performed intraoperatively and during the early postoperative period.
The primary outcomes include wound healing and postoperative complications related to the saphenous vein harvesting site. Secondary outcomes include clinical outcomes and functional capacity following surgery.
This trial may contribute to improving postoperative care and recovery in patients undergoing coronary artery bypass grafting.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 4
- Model description
- Participants will be randomly assigned to four parallel groups according to the saphenous vein harvesting technique and the use of photobiomodulation therapy: conventional harvesting with sham laser, conventional harvesting with photobiomodulation, no-touch harvesting with sham laser, and no-touch harvesting with photobiomodulation.
| Arm | Type | Receives |
|---|---|---|
| Conventional Harvesting + Sham laser | Sham comparator | Device: Sham Laser irradiation, Procedure: Conventional Saphenous Vein HarvestingPatients undergoing conventional saphenous vein harvesting with simulated laser application (sham). |
| Conventional Harvesting + Photobiomodulation | Experimental | Device: Photobiomodulation Therapy, Procedure: Conventional Saphenous Vein HarvestingPatients undergoing conventional saphenous vein harvesting with active photobiomodulation therapy applied to the surgical incision. |
| No-touch Harvesting + Sham laser | Sham comparator | Device: Sham Laser irradiation, Procedure: No-Touch Saphenous Vein HarvestingPatients undergoing saphenous vein harvesting using the no-touch technique with simulated laser application. |
| No-touch Harvesting + Photobiomodulation | Experimental | Device: Photobiomodulation Therapy, Procedure: No-Touch Saphenous Vein HarvestingPatients undergoing saphenous vein harvesting using the no-touch technique with active photobiomodulation therapy applied to the surgical incision. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients diagnosed with coronary artery disease scheduled to undergo elective coronary artery bypass grafting (CABG)
- Use of the saphenous vein as a graft for myocardial revascularization
- Ability to understand the study procedures and provide written informed consent
Key exclusion criteria (8 listed)
- Emergency coronary artery bypass surgery
- Previous surgery in the lower limb that prevents saphenous vein harvesting
- Active infection at the surgical site or lower limb
- Severe peripheral arterial disease in the lower limbs
- Hemodynamic instability preventing study protocol procedures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Photobiomodulation TherapyPhotobiomodulation will be applied using a cluster laser device (E-light, DMC Equipamentos Ltda., Brazil) with wavelength of 660 nm and output power of 100 mW. The therapy will be applied along the surgical incision of the saphenous vein harvesting site using a point technique with standardized spacing between application points. The intervention will be performed intraoperatively and during the early postoperative period. | Device | Conventional Harvesting + Photobiomodulation, No-touch Harvesting + Photobiomodulation |
| Sham Laser irradiationSimulated photobiomodulation therapy applied using the same laser device without emission of therapeutic laser energy. This sham procedure is used to maintain blinding of participants and outcome assessors. | Device | Conventional Harvesting + Sham laser, No-touch Harvesting + Sham laser |
| Conventional Saphenous Vein HarvestingConventional Saphenous Vein Harvesting refers to the traditional open surgical technique used to obtain the great saphenous vein for grafting procedures, most commonly in coronary artery bypass grafting (CABG). The procedure involves a continuous longitudinal incision along the course of the vein in the lower limb, allowing direct visualization and careful dissection of the vessel from surrounding tissues. Side branches are ligated or clipped, and the harvested vein is subsequently prepared for use as a vascular graft. The technique is performed under sterile surgical conditions by qualified surgeons. | Procedure or surgery | Conventional Harvesting + Photobiomodulation, Conventional Harvesting + Sham laser |
| No-Touch Saphenous Vein HarvestingNo-Touch Saphenous Vein Harvesting refers to a surgical technique for harvesting the great saphenous vein in which the vein is removed together with a pedicle of surrounding perivascular tissue, avoiding direct manual manipulation and excessive distension of the vessel. The procedure is performed through an open incision under sterile conditions, preserving the vein's adventitia, vasa vasorum, and surrounding connective tissue in order to minimize endothelial injury and maintain vascular integrity. Side branches are carefully ligated or clipped, and the harvested graft is prepared according to institutional surgical protocols for subsequent use in vascular or coronary artery bypass procedures. | Procedure or surgery | No-touch Harvesting + Photobiomodulation, No-touch Harvesting + Sham laser |
Primary outcome
Incidence of surgical wound complications at the saphenous vein harvesting site
Time frame: From postoperative hospitalization to 30 days and 3 months after surgery.
Occurance of one or more surgical wound complications at the saphenous vein harvesting site, including wound infection, necrosis, wound dehiscence, wound drainage or fluid accumulation.
14 secondary outcomes
Frequency and severity of adverse responses to photobiomodulation therapy
Time frame: From the first photobiomodulation therapy session until hospital discharge (Postoperative day 5 or earlier, if discharged).
All-cause mortality
Time frame: Hospital discharge, 30 days after discharge and 3 months after discharge
Hospital readmission
Time frame: 30 days and 3 months after discharge
Myocardial infarction
Time frame: Perioperative, 30 days after discharge and 3 months after discharge.
Length of stay in the intensive care unit (ICU)
Time frame: From date of surgery until ICU discharge (assessed up to 30 days).
Length of hospital stay
Time frame: From hospital admission until hospital discharge (assessed up to 60 days)
Plasma interleukin-1 (IL-1) levels
Time frame: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Plasma interleukin-6 (IL-6) levels
Time frame: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Plasma interleukin-8 (IL-8) levels
Time frame: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Plasma interleukin-10 (IL-10) levels
Time frame: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Plasma tumor necrosis factor-alpha (TNF-α) levels
Time frame: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Thiobarbituric acid reactive substances (TBARS) levels
Time frame: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Protein carbonylation (CPr) levels
Time frame: Preoperative period, immediately after surgery before photobiomodulation application, 20 minutes after ICU admission, and on postoperative days 2 to 5 or until hospital discharge.
Functional capacity assessed by the Six-Minute Walk Test
Time frame: One day before surgery, five days after surgery, 30 days after hospital discharge and 3 months after discharge.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- No-touch technique for saphenous vein graft harvesting in coronary artery bypass surgery safely improves graft patency: a meta-analysis of randomized controlled trials.Link provided by the sponsor.
- Oxygen uptake on-kinetics during six-minute walk test predicts short-term outcomes after off-pump coronary artery bypass surgery.Link provided by the sponsor.
- Effectiveness of low-intensity laser therapy on tissue repair following saphenectomy in patients who underwent coronary artery bypass graft: A randomized, double-blind study.Link provided by the sponsor.
- SUPERIOR SVG: no touch saphenous harvesting to improve patency following coronary bypass grafting (a multi-Centre randomized control trial, NCT01047449).Link provided by the sponsor.
- Pedicled no-touch saphenous vein graft harvest limits vascular smooth muscle cell activation: the PATENT saphenous vein graft study.Link provided by the sponsor.
- Detection and quantification of cytokines and other biomarkers.Link provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Artery Disease
Not yet recruitingPhase 1/2
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Heterozygous Familial Hypercholesterolemia (HeFH)
Active, not recruitingPhase 3
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
Coronary Artery Disease
RecruitingObservational study
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Metabolic Disease, Obesity
Active, not recruiting
Troponin in Acute Chest Pain to Risk Stratify and Guide EffecTive Use of Computed Tomography Coronary Angiography
Coronary Artery Disease
Recruiting
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
Cardiovascular Diseases, Myocardial Ischemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Photobiomodulation Therapy, Conventional Saphenous Vein Harvesting and No-Touch Saphenous Vein Harvesting in people with Coronary Artery Disease and Coronary Artery Bypass Graft (CABG), run by Federal University of São Paulo at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Solange Guizilini, PhD (+55 11 982887753, sguizilini@unifesp.br), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of surgical wound complications at the saphenous vein harvesting site (time frame: From postoperative hospitalization to 30 days and 3 months after surgery.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.